Purchase Articles & Bundles w/CE

My Cart

	Title	Publication Date	CE Expiration	CE Hours	Price
	HIV Infection: An Update on Antiretroviral Therapy ACPE #: 0428-0000-18-001-H02-P At the conclusion of this program, participants will be able to: List the antiretroviral regimens recommended for pre- and post-exposure prophylaxis, and describe their efficacy. Describe the current recommendations for starting antiretroviral therapy. Identify the recommended regimens for antiretroviral-naïve persons. Discuss the adverse effects and drug interactions of the most commonly used antiretroviral agents (ARVs) and classes. Advise patients about the administration of ARVs, monitoring parameters, and the importance of adherence.	01/20/2018	01/20/2021	2.0	$10.00

Sub Total: $6.95

To purchase one or more articles (CE included): Select your profession to display the correct list of articles, then click the green button to the left of the title(s) in the list below. This will add the selected article(s) to your cart.

Articles - $6.95 and up

Select Profession: View by Topic:

Title	Publication Date	CE Expiration	CE Hours
Pharmacy Law - A Focus on Opioid Prescriptions ACPE #: 0428-0000-19-008-H03-P At the conclusion of this program, participants will be able to: Explain the Corresponding Responsibility Doctrine; determine if a prescription is valid and identify “red flags” that should raise reasonable suspicion of a prescription’s validity. Summarize current laws and guidelines that are in place to limit the duration and dosing of opioid prescriptions. Discuss the importance of morphine milligram equivalents (MMEs) for commonly prescribed opioids. Provide examples of effective communication with patients and prescribers that helps ensure that prescriptions are being used safely and lawfully.	06/25/2019	06/25/2022	2.0
Cholesterol Management - Understanding the 2018 Guideline ACPE #: 0428-0000-19-007-H01-P At the conclusion of this program, participants will be able to: Compare and contrast the 2013 and 2018 ACC/AHA cholesterol guidelines; list key similarities and differences. Summarize the terms "primary prevention" and "secondary prevention" as applied to cardiovascular disease. Describe the risk assessment calculators that should be used for each patient to calculate the risk of developing ASCVD. List the 4 statin benefit groups; recognize which patients would be placed in each group. Recommend a statin regimen based on the group a patient is placed in and/or whether they are part of a special population at risk for ASCVD. Discuss guideline implementation strategies and provide patient counseling tips about statins and related muscle effects, liver dysfunction, and new-onset diabetes.	05/22/2019	05/22/2022	1.5
Cannabidiol (CBD) ACPE #: 0428-0000-19-006-H01-P At the conclusion of this program, participants will be able to: Summarize the legal considerations that surround marijuana and hemp plants. Describe the major active ingredients of both plants and explain how their physiological effects differ. State the potential clinical uses for cannabidiol (CBD), including the products that have been FDA-approved for certain indications. Discuss the clinical evidence to support the use of nonprescription CBD products. Discuss safety concerns with nonprescription CBD products, including potential drug interactions. Counsel a patient on what to look for in a nonprescription CBD product before purchasing it.	04/22/2019	04/22/2022	1.5
New Drugs 2018 ACPE #: 0428-0000-19-005-H01-P At the conclusion of this program, participants will be able to: For each of the drugs reviewed: List the FDA approved indication(s), state the recommended dose(s), and discuss the evidence supporting the drug’s approval and potential role(s) in therapy. Describe significant side effects and drug interactions. Provide 2-3 patient counseling tips. For drugs listed in Tables 2 and 3: List the generic/brand names, dosage form(s), FDA approved indication(s), and major safety concerns.	03/22/2019	03/22/2022	2.0
Dry Eye Disease ACPE #: 0428-0000-19-004-H01-P At the conclusion of this program, participants will be able to: Outline the cause(s) of dry eye disease and identify risk factors associated with its development. Be able to recognize dry eye disease symptoms and counsel a patient on self-care measures to improve symptoms. Discuss current treatment approaches for dry eye disease including goals of therapy and 4-step management. Describe the role of ocular lubricants and antiinflammatory agents in the management of dry eye disease, including their safety and administration. Discuss the role that topical and oral antibiotics may have in DED-related conditions.	02/22/2019	02/22/2022	1.5
Oral Agents for the Treatment of Metastatic Non-Small Cell Lung Cancer ACPE #: 0428-0000-19-001-H01-P At the conclusion of this program, participants will be able to: Describe the risk factors for lung cancer and how it is diagnosed. Discuss the overall treatment goal and general plan for managing non-small cell lung cancer (NSCLC). Discuss the currently recommended targeted treatment approaches and regimens for NSCLC. Counsel patients about the major adverse effects and drug interactions with oral targeted treatments for NSCLC; recommend management options.	01/23/2019	01/23/2022	1.5
Identifying Victims of Human Trafficking in the Health Care Setting ACPE #: 0428-0000-19-003-H04-P At the conclusion of this program, participants will be able to: Describe the types of human trafficking Outline key factors that place a person at greater risk of being a victim of human trafficking Recognize general indicators that a person may be a victim of human trafficking as well as validated assessment tools for identifying a human trafficking victim Identify methods for reporting human trafficking to include the national hotline. Outline referral options for legal services as well public and private social services available for rescue, food, clothing and shelter Describe procedures for sharing information related to human trafficking with a patient	01/22/2019	01/21/2022	2.0
Texas Pharmacy Law: Expanding the Role of Pharmacists to Administer Epinephrine ACPE #: 0428-0000-19-002-H03-P At the conclusion of this program, participants will be able to: Describe the administrative, notification, and reporting requirements of a pharmacist who administers epinephrine in an emergency. Outline the liability protections outlined by 22 TAC §295.16 titled “Administration of Epinephrine by a Pharmacist” Recognize the importance of being prepared to respond to an anaphylaxis emergency in the pharmacy setting	01/22/2019	01/22/2022	1.0
Heartburn: Appropriate Use of OTC Medications ACPE #: 0428-0000-18-024-H01-P At the conclusion of this program, participants will be able to: Describe heartburn and indicate when self-care with over-the-counter (OTC) medications is appropriate. Recommend lifestyle changes that may help prevent or reduce heartburn. Describe the main differences among antacids, histamine-2-receptor antagonists (H2RAs), and proton pump inhibitors (PPIs) in the treatment of heartburn. Educate patients about the proper administration of each. Summarize safety concerns for OTC heartburn medications including potential drug interactions, use in special populations, and the unique concerns with PPI therapy.	12/20/2018	12/20/2021	1.5
Direct-Acting Oral Anticoagulants ACPE #: 0428-0000-18-023-H01-P At the conclusion of this program, participants will be able to: Educate patients with non-valvular AF about stroke prevention. Discuss the signs of a DVT and its treatment. Discuss the advantages and disadvantages of DOACs compared with warfarin. Recognize the FDA-approved indications for different DOACs. List DOAC side effects, dosing regimens, and drug interactions. Discuss their use in patients with kidney impairment. Discuss bleeding management and the use of DOAC reversal agents. Counsel patients about the signs of bleeding linked to anticoagulation.	11/23/2018	11/23/2021	1.5
Managing Chronic Pain - A Pain Management & Opioid CE Program ACPE #: 0428-0000-18-022-H01-P At the conclusion of this program, participants will be able to: Describe the differences among chronic pain classifications. Describe the general treatment approach for noncancer pain. Describe how COX selectivity relates to the potential toxicity of different NSAIDs and list major precautions for all NSAIDs. Name 4 antidepressants and 3 anticonvulsants that may be effective for certain types of chronic pain; list precautions and potential side effects for each. Explain how different chemical structures of opioids contribute to their clinical effects. Advise other providers and patients regarding opioid side effects, drug-drug interactions, pharmacogenomic variability, and opioid rotation.	10/23/2018	10/23/2021	1.5
New Considerations in Diabetes Management ACPE #: 0428-0000-18-010-H01-P At the conclusion of this program, participants will be able to: Discuss the current recommendations for continuous glucose monitoring (CGM) in patients with diabetes. Describe how personal CGM devices work and list the advantages and disadvantages of currently available products. Outline important considerations with the use of SGLT2 inhibitors, including cardiovascular benefits, use in patients with kidney dysfunction, and potentially serious side effects. Discuss new developments in insulin therapy, including ultra-rapid acting insulins and biosimilars (follow-on biologic insulins). Counsel a patient on converting from one insulin type to another. Discuss the proposed subcategories of T2DM. Be able to apply patient-centered treatment recommendations from the ADA and AACE/ACE.	09/21/2018	09/21/2021	1.5
Influenza Update - An Immunization CE Program ACPE #: 0428-0000-18-009-H06-P At the conclusion of this program, participants will be able to: Describe the influenza disease course, symptoms, and diagnostic tests. Recognize people at high risk for flu complications. Describe the determinants for influenza vaccine efficacy. Discuss the rationale for the suboptimal efficacy of the 2017-2018 vaccines, and recommendations for the use of LAIV vaccine in 2018-2019. State the indications, dosing requirements (children and adults), administration routes, side effects, and contraindications for 2018-2019 influenza vaccinations. Discuss the use of antiviral drugs for influenza treatment and prevention; be able to apply the current recommendations for their use.	08/23/2018	08/23/2021	2.0
Opioid Prescriptions: Balancing Misuse or Abuse With Pain Control - Florida Board Approved ACPE #: 0428-0000-18-008-H05-P At the conclusion of this program, participants will be able to: Discuss opioid use in the US today, and the potential barriers to obtaining legitimate opioid medications. Review the benefits and risks of using opioids for chronic pain; list risk factors for opioid overdose and death. List the elements of safe and effective opioid prescribing and explain how to integrate the use of a prescription drug monitoring program (PDMP) database when determining the validity of opioid prescriptions. Discuss how to effectively communicate with patients and prescribers in order to validate the legitimacy of an opioid prescription. Describe 2 indicators of potential prescription opioid diversion or misuse.	08/01/2018	08/01/2021	2.0
Managing Psoriasis ACPE #: 0428-0000-18-007-H01-P At the conclusion of this program, participants will be able to: Discuss the epidemiology and contributing factors for the development of psoriasis. Describe psoriasis symptoms and how body surface area and the Psoriasis Area Severity Index (PASI) are used in assessing psoriasis severity. List commonly used topical treatments. Counsel patients regarding administration, side effects, and precautions. Compare and contrast systemic treatments used for psoriasis, including effectiveness, side effects, and precautions.	06/23/2018	06/23/2021	1.5
Medication Adherence: A Critical Component of Healthcare - A Patient Safety CE Program ACPE #: 0428-0000-18-006-H05-P At the conclusion of this program, participants will be able to: Define medication adherence and describe different ways that patients may be nonadherent. Discuss the clinical and economic impact of nonadherence, including its contribution to poor outcomes in chronic disease. List risk factors and red flags for medication nonadherence, and describe methods/tools for identifying it. Discuss patient-, medication-, condition-, socioeconomic-, provider-, and healthcare system/team-related barriers to medication adherence. Describe strategies and resources that healthcare professionals can use to improve medication adherence.	05/23/2018	05/23/2021	1.5
Hypertension Update 2018 ACPE #: 0428-0000-18-005-H01-P At the conclusion of this program, participants will be able to: Discuss the JNC 8 and 2017 ACC/AHA guidelines, and describe at least 3 significant differences between them. State the ACC/AHA definitions for normal blood pressure (BP), elevated BP, stage 1 hypertension and stage 2 hypertension. Provide recommendations for initial antihypertensive therapy based on JNC 8 and ACC/AHA guidelines. Explain the current role of b-blockers in hypertension management. Discuss considerations in the choice of ACE inhibitors vs. ARBs; hydrochlorothiazide vs. chlorthalidone; and dihydropyridine (DHP) vs. nonDHP calcium channel blockers. Discuss the ACC/AHA recommendations for nondrug management of hypertension, including BP monitoring.	04/23/2018	04/23/2021	1.5
New Drugs 2017 ACPE #: 0428-0000-18-004-H01-P At the conclusion of this program, participants will be able to: For each of the drugs reviewed: A. List the FDA approved indication(s), state the recommended dose(s), and discuss the evidence supporting the drug’s approval and potential role(s) in therapy. B. Describe significant side effects and drug interactions. Provide 2-3 patient counseling tips For drugs listed in Table 2: A. List the generic/brand names, dosage form(s), FDA approved indication(s), and major safety concerns.	03/22/2018	03/22/2021	2.0
HIV Infection: An Update on Antiretroviral Therapy – Florida Board-Approved Edition ACPE #: 0428-0000-18-003-H02-P At the conclusion of this program, participants will be able to: List the antiretroviral regimens recommended for pre- and post-exposure prophylaxis, and describe their efficacy. Describe the current recommendations for starting antiretroviral therapy. Identify the recommended regimens for antiretroviral-naïve persons. Discuss the adverse effects and drug interactions of the most commonly used antiretroviral agents (ARVs) and classes. Advise patients about the administration of ARVs, monitoring parameters, and the importance of adherence.	03/15/2018	03/15/2021	2.0
Depression: More Reasons & Options for Recovery ACPE #: 0428-0000-18-002-H01-P At the conclusion of this program, participants will be able to: Describe the criteria for diagnosing depression and the rationale for using the PHQ-9 (patient health questionaire) and the MDQ (mood disorder questionaire) as additional screening tools. Discuss the role of psychotherapy in the treatment of depression. Compare the advantages (or disadvantages) of using SSRIs, SNRIs, multiple mechanism serotonergic agents, bupropion, and mirtazapine in the treatment of depression. Discuss combination therapy for the treatment of depression. Appraise the role of complementary therapeutics such as diet, exercise, fish oil, SAM-e, vitamin D, folate/methylfolate, and St. John’s wort in the management of major depression.	02/23/2018	02/23/2021	1.5
Fluoroquinolones Warnings & Side Effects - What You Need to Know ACPE #: 0428-0000-17-012-H01-P At the conclusion of this program, participants will be able to: Describe the spectrum of activity of fluoroquinolones and discuss dosing considerations. List 3 types of infections for which fluoroquinolones may be indicated, and 3 types for which their use should usually be avoided. Discuss serious side effects of fluoroquinolones, including: tendon damage, peripheral neuropathy, central nervous system effects, cardiac arrhythmias, gastrointestinal side effects, blood glucose abnormalities, ocular toxicity, and skin/allergic reactions. Discuss the use of fluoroquinolones in children and adolescents, and during pregnancy and breastfeeding. Counsel patients with new fluoroquinolone prescriptions about proper administration, common side effects, drug interactions, and serious side effects for which they should contact their prescriber.	12/23/2017	12/23/2020	1.5
Smoking Cessation For the Busy Clinician ACPE #: 0428-0000-17-011-H01-P At the conclusion of this program, participants will be able to: Discuss tobacco dependence and the symptoms of withdrawal from nicotine. List the 5 key components of comprehensive smoking cessation counseling. Apply the abbreviated “Ask-Advise-Refer” counseling approach. Be familiar with smoking cessation resources for patient referral. Assist patients with smoking cessation product selection and dosing based on tobacco use history. Discuss the advantages and disadvantages of each product. Describe the types of patients who might benefit from combination therapy. Discuss the contraindications and potential adverse effects of the FDA-approved medications for smoking cessation.	11/22/2017	11/22/2020	2.0
Osteoarthritis Management ACPE #: 0428-0000-17-010-H01-P At the conclusion of this program, participants will be able to: Describe the benefits (or lack of benefit) of nondrug therapies (eg, exercise, physical therapy, weight loss, tai chi, acupuncture) in the management of hip and knee osteoarthritis (OA). Discuss the efficacy and side effect/safety profiles of acetaminophen, NSAIDs (oral and topical), tramadol, capsaicin, and duloxetine. Recommend analgesic therapy for OA based on efficacy and patients’ coexisting conditions. Discuss the potential benefits of complementary and alternative medicine, including the use of supplements, in OA management.	10/23/2017	10/23/2020	1.5
Diabetes Update ACPE #: 0428-0000-17-009-H01-P At the conclusion of this program, participants will be able to: Discuss the results of the Diabetes Prevention Program (DPP) study. List the risk factors and criteria for prediabetes. Name 3 diabetes medications that may be considered for prediabetes when lifestyle therapy alone is inadequate. Describe Diabetes Self-Management Education and Support (DSME/S) programs and their accreditation/recognition. Define food insecurity. Discuss causes of health disparities in populations, and approaches to reducing them. Educate patients who cannot afford prescription insulin about the proper use of OTC insulin. Discuss the Cardiovascular Outcomes Studies (CVOTs) and cardiovascular benefits of at least 3 diabetes medications.	09/23/2017	09/23/2020	1.5
Immunization Update: A Focus on Medical Indications for Vaccines in Adults ACPE #: 0428-0000-17-008-H06-P At the conclusion of this program, participants will be able to: Discuss vaccine-specific indications and contraindications for patients with altered immunocompetence (including HIV infection and asplenia). Discuss vaccine-specific indications and contraindications for patients with diabetes, cardiovascular disease, and chronic lung, liver, or kidney disease. Describe vaccine-specific recommendations for pregnant women, men who have sex with men, and for patients with egg allergy.	08/23/2017	08/23/2020	2.0
Pharmacy Law: Regulatory Developments Affecting Pharmacy Practice ACPE #: 0428-0000-17-007-H03-P At the conclusion of this program, participants will be able to: Discuss the differences between traditional compounding and compounding at outsourcing facilities and the regulations that apply to each. Compare sections 503A and 503B of the Compounding Quality Act. Explain the Drug Supply Chain Security Act as it applies to various parts of the pharmaceutical distribution chain and recognize the key provisions of the Act to be implemented by 2023. Define what is meant by a biosimilar product, and discuss the FDA’s criteria for interchangeability. Apply the Drug Disposal Act implemented in 2014 to your practice. Identify the allowed methods of controlled substance disposal and requirements for each. Summarize the advantages of the rescheduling of hydrocodone combination products to Schedule II, and the regulation under the Comprehensive Addiction and Recovery Act (CARA) regarding partial filling of Schedule II drugs.	07/06/2017	07/06/2020	2.0
Update on Medication Errors and Adverse Drug Events-Florida Board-Approved Edition ACPE #: 0428-0000-17-006-H05-P At the conclusion of this program, participants will be able to: Discuss the steps in the medication use process and the types of medication errors that may occur. Describe the relationship between medication errors and adverse drug events (ADEs). List the drug classes that are prone to emergency department visits due to ADEs. Describe the main recommendations from national organizations (eg, IOM, ASHP, JCPP, and DHHS) for improving medication safety. List the steps involved in the Pharmacists' Patient Care Process (PPCP) and specific risk reduction strategies to prevent medication errors recommended by the ISMP. Review the evidence supporting pharmacist interventions to improve medication safety, including adherence, and reducing medication discrepancies during transitions of care. Discuss how the use of health information technology (HIT) can have a positive impact on medication safety. List possible disadvantages of HIT.	05/20/2017	05/20/2020	2.0
Antibiotic Stewardship: Improving Use In The Community ACPE #: 0428-0000-17-005-H01-P At the conclusion of this program, participants will be able to: Review mechanisms of antibiotic resistance and its spread. Describe current antibiotic resistance trends in the US. Describe the extent of overuse and misuse of antibiotics in the US and the patient harms that can occur with antibiotic use. Review the CDC’s recommendations for diagnosis and treatment of common outpatient respiratory infections. Discuss the CDC's 4 components of an outpatient antibiotic stewardship program. Provide examples of how community providers may be involved in stewardship programs and strategies that can help improve antibiotic use.	04/20/2017	04/20/2020	1.5
New Drugs 2016 - 2017 ACPE #: 0428-0000-17-003-H01-P At the conclusion of this program, participants will be able to: For each of the drugs reviewed: List the FDA approved indication(s), state the recommended dose(s), and discuss the evidence supporting the drug’s approval and potential role(s) in therapy. For each of the drugs reviewed: Describe significant side effects and drug interactions. Provide 2-3 patient counseling tips. For each drug listed in Table 2: List the generic/brand names, dosage form(s), FDA approved indication(s), and major safety concerns.	03/22/2017	03/22/2020	2.0
Pharmacy Law: Determining the Legitimacy of Opioid Prescriptions ACPE #: 0428-0000-17-004-H03-P At the conclusion of this program, participants will be able to: Describe the complexities healthcare professionals face with chronic pain management that make it difficult to ensure adequate pain treatment in appropriate patients. Explain the Corresponding Responsibility Doctrine and how it has been applied to court cases involving pharmacists. List methods that can assist pharmacists in determining the legitimacy of opioid prescriptions. Discuss the legally accepted standards for the treatment of pain in an addict.	03/20/2017	03/20/2018	2.0
Chronic Insomnia ACPE #: 0428-0000-17-002-H01-P At the conclusion of this program, participants will be able to: Review the prevalence, pathophysiology, and consequences of insomnia. Explain the recommendations and rationale for cognitive-behavioral therapy for insomnia. Be able to counsel patients regarding sleep hygiene tips, stimulus control measures, and potential problems with the use of OTC sleep medications. Describe the efficacy, indications, side effects, and drug interactions of GABA-A receptor modulators (including benzodiazepines and Z-drugs), ramelteon, and suvorexant. Discuss the role of antidepressants and antipsychotics in the treatment of insomnia.	02/23/2017	02/23/2020	1.5
Hormonal Contraceptives ACPE #: 0428-0000-17-001-H01-P At the conclusion of this program, participants will be able to: Compare and contrast the methods of hormonal contraception provided in a pharmacy; review their pharmacology and relative effectiveness. Identify the most common side effects related to the estrogen and progestin components of hormonal contraceptives. Discuss the more serious risks associated with the use of estrogen-containing contraceptives. Counsel patients about their choice of hormonal contraceptive method, including the noncontraceptive benefits. Provide instructions to a woman who has missed one or more of her contraceptive doses. Apply the CDC Medical Eligibility Criteria to determine whether a woman is a candidate for hormonal contraceptives. Outline the CDC’s recommended steps that a clinician should follow when providing contraceptives.	01/22/2017	01/22/2020	1.5
Medical Marijuana ACPE #: 0428-0000-16-011-H01-P At the conclusion of this program, participants will be able to: Identify the main active constituents of cannabis and the physiologic processes that these may affect. List common conditions for which medical marijuana is used and the current supporting evidence (if any). Describe the acute effects and long-term risk of cannabis, and its effect on the reward pathway of the brain. Review various dosing methods for medical marijuana and the pharmacokinetic differences among them.	12/23/2016	12/23/2019	1.5
Inflammatory Bowel Disease: A Focus On Biologics ACPE #: 0428-0000-16-010-H01-P At the conclusion of this program, participants will be able to: Discuss the clinical course of IBD. Describe the major differences between Crohn's disease and ulcerative colitis. Discuss the goals of therapy and list the traditional medication classes available for IBD management. List the TNF blockers, integrin inhibitors, and the IL-12/23 antagonist that are used for treatment of IBD; discuss their efficacy, adverse effects, precautions and contraindications. Define what is meant by a biosimilar product, and describe how it differs from a generic. List 2 biosimilar products that are FDA-approved for treatment of IBD.	11/23/2016	11/23/2019	1.5
Hepatitis C Treatment: Gone Viral ACPE #: 0428-0000-16-009-H01-P At the conclusion of this program, participants will be able to: Describe the prevalence and general course of HCV disease, risk factors, and factors that may worsen HCV disease. Outline general antiviral treatment considerations, including social factors, HCV genotype, disease severity, and coexisting medical conditions. Describe the DAA regimens for HCV genotypes 1, 2, and 3, including dosing, duration, indications, contraindications, and potential drug-drug interactions. List common side effects of DAA agents and management strategies. Counsel patients on the importance of adherence.	10/23/2016	10/23/2019	1.5
Diabetes Update: The New Concentrated Insulin Products ACPE #: 0428-0000-16-008-H01-P At the conclusion of this program, participants will be able to: Describe the current blood glucose and A1C treatment goals according to national guidelines, and the role of insulin in managing T2DM. List potential candidates for concentrated insulin products and the rationale(s) for using these products. Name the 4 available concentrated insulin products. Describe the pharmacokinetic and clinical properties of each product, and list an advantage of each. Instruct patients on proper insulin pen use and counsel them on the recognition and management of hypoglycemia.	10/20/2016	10/20/2019	1.5
Dementia: Managing Neuropsychiatric Symptoms ACPE #: 0428-0000-16-007-H01-P At the conclusion of this program, participants will be able to: Describe the neuropsychiatric symptoms of dementia and the factors that may lead to problem behaviors. Discuss how the type of dementia may lead to certain behavioral symptoms and impact treatment choice. Review the non-drug and drug therapy considerations for common behavioral and psychiatric symptoms of dementia. Describe the role of the combination pill containing dextromethorphan and quinidine. Discuss the efficacy, side effects, and dosing for the most frequently used antipsychotics and antipressants for NPSD. List drug classes that have not been proven effective and/or have more risk than benefit for the management of NPSD.	08/20/2016	08/20/2019	1.5

Available Bundles

Bundle Name/Title	CE Hours	Price
Pharmacology CE Bundle		$39.95
Chronic Insomnia (Pharmacist/Nurse) Pub Date: 02/23/2017 CE Expiration: 02/23/2020 ACPE #: 0428-0000-17-002-H01-P At the conclusion of this program, participants will be able to: Review the prevalence, pathophysiology, and consequences of insomnia. Explain the recommendations and rationale for cognitive-behavioral therapy for insomnia. Be able to counsel patients regarding sleep hygiene tips, stimulus control measures, and potential problems with the use of OTC sleep medications. Describe the efficacy, indications, side effects, and drug interactions of GABA-A receptor modulators (including benzodiazepines and Z-drugs), ramelteon, and suvorexant. Discuss the role of antidepressants and antipsychotics in the treatment of insomnia.	1.5
Diabetes Update: The New Concentrated Insulin Products (Pharmacist/Nurse) Pub Date: 10/20/2016 CE Expiration: 10/20/2019 ACPE #: 0428-0000-16-008-H01-P At the conclusion of this program, participants will be able to: Describe the current blood glucose and A1C treatment goals according to national guidelines, and the role of insulin in managing T2DM. List potential candidates for concentrated insulin products and the rationale(s) for using these products. Name the 4 available concentrated insulin products. Describe the pharmacokinetic and clinical properties of each product, and list an advantage of each. Instruct patients on proper insulin pen use and counsel them on the recognition and management of hypoglycemia.	1.5
Hepatitis C Treatment: Gone Viral (Pharmacist/Nurse) Pub Date: 10/23/2016 CE Expiration: 10/23/2019 ACPE #: 0428-0000-16-009-H01-P At the conclusion of this program, participants will be able to: Describe the prevalence and general course of HCV disease, risk factors, and factors that may worsen HCV disease. Outline general antiviral treatment considerations, including social factors, HCV genotype, disease severity, and coexisting medical conditions. Describe the DAA regimens for HCV genotypes 1, 2, and 3, including dosing, duration, indications, contraindications, and potential drug-drug interactions. List common side effects of DAA agents and management strategies. Counsel patients on the importance of adherence.	1.5
Opioid Prescriptions: Balancing Misuse or Abuse With Pain Control - Florida Board Approved (Pharmacist/Nurse) Pub Date: 06/20/2016 CE Expiration: 06/20/2019 ACPE #: 0428-0000-16-006-H05-P At the conclusion of this program, participants will be able to: Discuss opioid use in the US today, and the potential barriers to obtaining legitimate opioid medications. Review the benefits and risks of using opioids for chronic pain; list risk factors for opioid overdose and death. List the elements of safe and effective opioid prescribing and explain how to integrate the use of a prescription drug monitoring program (PDMP) database when determining the validity of opioid prescriptions. Discuss how to effectively communicate with patients and prescribers in order to validate the legitimacy of an opioid prescription. Describe 2 indicators of potential prescription opioid diversion or misuse.	2.0
Osteoarthritis Management (Pharmacist/Nurse) Pub Date: 10/23/2017 CE Expiration: 10/23/2020 ACPE #: 0428-0000-17-010-H01-P At the conclusion of this program, participants will be able to: Describe the benefits (or lack of benefit) of nondrug therapies (eg, exercise, physical therapy, weight loss, tai chi, acupuncture) in the management of hip and knee osteoarthritis (OA). Discuss the efficacy and side effect/safety profiles of acetaminophen, NSAIDs (oral and topical), tramadol, capsaicin, and duloxetine. Recommend analgesic therapy for OA based on efficacy and patients’ coexisting conditions. Discuss the potential benefits of complementary and alternative medicine, including the use of supplements, in OA management.	1.5
Renewal CE Bundle		$19.95
Antibiotic Stewardship: Improving Use In The Community (Pharmacist/Nurse) Pub Date: 04/20/2017 CE Expiration: 04/20/2020 ACPE #: 0428-0000-17-005-H01-P At the conclusion of this program, participants will be able to: Review mechanisms of antibiotic resistance and its spread. Describe current antibiotic resistance trends in the US. Describe the extent of overuse and misuse of antibiotics in the US and the patient harms that can occur with antibiotic use. Review the CDC’s recommendations for diagnosis and treatment of common outpatient respiratory infections. Discuss the CDC's 4 components of an outpatient antibiotic stewardship program. Provide examples of how community providers may be involved in stewardship programs and strategies that can help improve antibiotic use.	1.5
Diabetes Update (Pharmacist/Nurse) Pub Date: 09/23/2017 CE Expiration: 09/23/2020 ACPE #: 0428-0000-17-009-H01-P At the conclusion of this program, participants will be able to: Discuss the results of the Diabetes Prevention Program (DPP) study. List the risk factors and criteria for prediabetes. Name 3 diabetes medications that may be considered for prediabetes when lifestyle therapy alone is inadequate. Describe Diabetes Self-Management Education and Support (DSME/S) programs and their accreditation/recognition. Define food insecurity. Discuss causes of health disparities in populations, and approaches to reducing them. Educate patients who cannot afford prescription insulin about the proper use of OTC insulin. Discuss the Cardiovascular Outcomes Studies (CVOTs) and cardiovascular benefits of at least 3 diabetes medications.	1.5
Immunization Update: A Focus on Medical Indications for Vaccines in Adults (Pharmacist/Nurse) Pub Date: 08/23/2017 CE Expiration: 08/23/2020 ACPE #: 0428-0000-17-008-H06-P At the conclusion of this program, participants will be able to: Discuss vaccine-specific indications and contraindications for patients with altered immunocompetence (including HIV infection and asplenia). Discuss vaccine-specific indications and contraindications for patients with diabetes, cardiovascular disease, and chronic lung, liver, or kidney disease. Describe vaccine-specific recommendations for pregnant women, men who have sex with men, and for patients with egg allergy.	2.0

Add Optional Items

Imprinted small 6 ring binder for index cards - $8.50

Imprinted large 3 ring binder for issue storage - $9.00

Article Deliver Options Email: Single articles will be emailed as attachments immediately after purchase; Package purchases will allow for immediate access of articles online, with email confirmation of order and access information.
U.S. First Class Mail: Your items will be mailed within 24 hours of purchase, M-F. $2.00 additional for shipping and handling.

Your Information

I already have an account and will login

I am a new user and will create a new account.

Company Name:

First Name:*

Last Name:*

Address Line1:*

Address Line2:

City:*

State/Province:*

Zip/Postal Code:*

Country:*

Phone:

Fax:

Email:*

Profession:*

NABP e-Profile ID:

Date of Birth (MMDD):

* Pharmacists and Technicians: NABP e-Profile ID and DOB are required for credit reporting to CPE Monitor.

Order Total: $0.00

View Cart

Your Billing Details

Card Type:*

Name on Card:*

Card Number:*

Card Security Code:*

Expiration:*

We Protect Your Privacy:
In order to provide you with all the services included in your subscription and grant you access to this site, Continuing Education Network, Inc. obtains information such as your name, address, email address, phone number, and payment information. We treat this information as confidential and use it to provide you with the best service possible.

Continuing Education Network, Inc. has NEVER released any of this information to any outside organization for such organization's own commercial or marketing use and has a policy against doing so. We do not engage in renting out, selling, or trading names of subscribers or any information about any subscriber.

Continuing Education Network, Inc. does not allow any other organization to send you unsolicited emails about any products or services. We may send you information about your subscription, your continuing education credits, or our own services. We do not gather data or track your use of any website other than our own. We invite you to ask us about any privacy concern you may have by calling 1-800-798-3353.